Topic: Eli Lilly

The "Wolverine" peptide stack has gained popularity for muscle growth, but medical experts warn of severe risks including pancreatitis and potential melanoma. Many peptides sold online from Chinese sources lack human safety trials and vary wildly in purity (50% to 300%), leading to accidental overdoses. Pharmaceutical companies like Eli Lilly are now moving to regulate these substances as they gain mainstream attention.

Eli Lilly is developing a new obesity medication called Retatrutide, which targets three different hormones (GLP-1, GIP, and glucagon). Clinical trials show patients lost an average of 70 pounds over 80 weeks, significantly outperforming placebos. The hosts discuss whether this is simply a repackaged peptide that is already available through "peptide dealers."

Eli Lilly is developing Rettatrutide, a new obesity drug that targets three hormones and reportedly leads to a 28% weight loss, comparable to bariatric surgery. While medical professionals call it "game-changing," critics point to side effects like "joy loss," where patients lose interest in food, sex, and other pleasures. The drug is expected to be submitted for FDA approval by the end of the year.

Novo Nordisk is cutting the price of Ozempic to compete with Eli Lilly's weight loss drugs, Monjaro and ZepBound. Dr. Celine Gounder discusses the "price war" and the effectiveness of these medications. A new side effect dubbed "Ozempic vulva," involving loose skin in the vaginal area, is highlighted as a consequence of rapid weight loss.

HHS Secretary Robert F. Kennedy Jr. testified before Congress regarding the threat of over-reliance on Chinese pharmaceuticals. Kennedy highlighted the "Thousand Talents Program" as a vehicle for IP theft and claimed the NIH has funded Chinese military scientists performing bioweapons research. He noted that Eli Lilly is currently building nine new factories in the U.S. to secure the domestic supply chain.

Pharmaceutical giants Eli Lilly and Novo Nordisk are engaging in a price war for obesity drugs by selling directly to consumers and bypassing insurance companies. Eli Lilly is offering Zepbound at a significant discount for patients who pay out-of-pocket. This shift highlights the "insurance scam" where manufacturers can make more profit by cutting out the middleman and lowering prices for direct buyers.

The FDA has approved the weight-loss drug Zepbound to treat obstructive sleep apnea. Medical correspondents report that the drug could effectively cure symptoms in 40% of patients. The hosts discuss the potential for Medicare and Medicaid to cover the high cost of these injectable medications, estimated at $30 billion over ten years.

Eli Lilly announced it will sell its weight loss drug Zepbound directly to consumers for half the retail price if their insurance does not cover it. The hosts point out that the company still profits at this lower price, highlighting the extreme markups typically charged to insurance providers and Medicare.

The FDA has approved Eli Lilly's new Alzheimer's medication, Kisunla (donanemab), designed to slow the progression of early-stage dementia. The hosts discuss the drug's $695-per-vial cost and speculate on its potential use for high-profile political figures showing signs of cognitive decline.

The ABC special on weight loss drugs featured prominent doctors who admitted to serving as paid consultants for pharmaceutical giants Eli Lilly and Novo Nordisk. These physicians argued that patients may need to remain on GLP-1 medications for life to manage the "disease" of obesity. Critics compare this marketing strategy to the early promotion of OxyContin, alleging that pharmaceutical companies are using media platforms to normalize long-term drug dependency.

Pharmaceutical giant Eli Lilly has partnered with Amazon Pharmacy to provide home delivery of its weight-loss drug Zepbound. The "LillyDirect" program aims to simplify access to the medication, which the hosts view as a sign of the increasingly commercialized and automated medical system.

Pharmaceutical giants Novo Nordisk and Eli Lilly are seeing record stock highs as they transition from injectable weight loss drugs to oral pill forms. Early trials of Novo Nordisk's pill, amicrotin, showed users lost 13% of their weight over 12 weeks. The industry is pivoting toward pills to lower costs and increase accessibility, with Medicare and Medicaid expected to eventually cover these treatments.

Eli Lilly has launched "Lilly Direct," a website allowing consumers to obtain prescriptions for the weight loss drug Zepbound via telehealth. In response, Novo Nordisk and other health advocates have warned about the dangers of buying "counterfeit" or "black market" versions of Ozempic online. Sharon Osbourne is cited as an example of the extreme weight loss results associated with these medications.

New research suggests that weight-loss drugs like Ozempic and Wegovy are associated with a lower risk of suicidal thoughts. Additionally, pharmaceutical giant Eli Lilly launched "Lilly Direct," a service that ships medications directly to consumers via telehealth prescriptions. This move toward bypassing traditional doctor visits is criticized as a potential risk to the established medical industry.

A report comparing Mounjaro and Ozempic identifies Mounjaro as the "clear winner" for weight loss. The hosts argue that the pharmaceutical industry is lobbying for Medicare to cover these expensive drugs by reclassifying obesity as a disease, which would force private insurers to follow suit and create a massive taxpayer-funded revenue stream.

The FDA approved Eli Lilly’s drug Zepbound for chronic weight management, which is a rebranded version of the diabetes drug Mounjaro. Financial analysts describe the "obesity opportunity" as potentially the largest pharmaceutical market in history, with marketing budgets expected to reach record highs.

An examination of the FDA's use of the term "chronic weight management" for Zepbound. The drug's safety warnings include the risk of thyroid C-cell tumors observed in rat studies, though the implications for human health remain officially unknown.

Discussion of the $1,000 monthly list price for weight loss drugs and the struggle for insurance reimbursement. The segment highlights the disparity between manufacturing costs and retail prices, while mocking the branding of drugs like Zepbound.

Manufacturers Novo Nordisk and Eli Lilly are facing lawsuits over claims that popular weight loss drugs Ozempic and Mounjaro cause severe stomach paralysis. A Louisiana woman alleges the drugs led to violent illness and emergency room visits. Despite these legal challenges, demand for GLP-1 agonists remains high, even as some insurance systems, like the University of Texas, begin to limit coverage.

Weight loss giant Jenny Craig is closing its operations after 40 years, citing competition from prescription drugs like Ozempic. The hosts discuss the shift in the weight loss industry toward pharmaceutical solutions, noting that Weight Watchers has also moved into the telehealth space to prescribe these medications. They warn of potential side effects like "Ozempic face" and hair loss.